Table 3.
TEAEs occurring in >2% of subjects during first-line triple therapy | ||
---|---|---|
Preferred term* | VPZ/AMX/CLR (n=329) | LPZ/AMX/CLR (n=321) |
Diarrhoea | 41 (12.5) | 49 (15.3) |
Nasopharyngitis | 18 (5.5) | 15 (4.7) |
Dysgeusia | 13 (4.0) | 10 (3.1) |
TEAEs occurring in >2% of subjects during second-line triple therapy | ||
Preferred term* | VPZ/AMX/MTZ (n=50) | |
Diarrhoea | 2 (4.0) | |
Flatulence | 2 (4.0) | |
Nasopharyngitis | 2 (4.0) | |
Alanine aminotransferase increased | 2 (4.0) | |
Aspartate aminotransferase increased | 2 (4.0) |
Data are expressed as number of subjects with percentage in parentheses.
*MedDRA (V.16.0).
AMX, amoxicillin; CLR, clarithromycin; LPZ, lansoprazole; MTZ, metronidazole; TEAE, treatment-emergent adverse event; VPZ, vonoprazan.